The emerging importance of attention and the speed of cognitive function in ageing and dementia research

CPD Bulletin Old Age Psychiatry

Volumn 3, Issue 1, 2001, Pages 11-15

  Wesnes, K A ^a   Bullock, R ^a  

^a Cognitive Drug Research Ltd ^*  (United Kingdom)

Author keywords

Alzheimer's disease; Attention; Computerized cognitive assessment; Dementia with lewy bodies; Mild cognitive impairment

Indexed keywords

1,2,3,4 TETRAHYDRO 1 METHYL 8 (2 MORPHOLINYLMETHOXY)QUINOLINE; CHOLINERGIC RECEPTOR AFFECTING AGENT; CHOLINESTERASE INHIBITOR; GALANTAMINE; TACRINE; VELNACRINE;

AGING; ALZHEIMER DISEASE; ATTENTION; AUTOMATION; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPUTER SYSTEM; DEMENTIA; DRUG EFFICACY; HUMAN; LEWY BODY; MEMORY; PSYCHOLOGIC ASSESSMENT; REVIEW; VELOCITY;

EID: 0034783242     PISSN: 14642514     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. The value of assessing cognitive function in drug development
2. Quantifying fluctuation in dementia with Lewy Bodies, Alzheimer's disease and vascular dementia
3. Effects of ageing on cognitive function
4. The cognitive profile of unmedicated schizophrenic patients in relation to controls
5. Validity of a cognitive computerized assessment system in brain-injured patients
6. Cognitive performance in hypertensive and normotensive older subjects
7. Computerized assessment of cognitive function in acute stroke
8. The effect of a 50Hz magnetic field on cognitive function in humans
9. The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - Is speed of the essence?
10. Objective Psychometric Tests in Clinical Trials of Dementia Drugs
11. The cognitive drug research computerised assessment system for demented patients: A validation study
12. The pathology of attention of the dementias
13. The effects of psychotropic drugs on human behaviour
14. The extent of the involvement of cholinergic deterioration in the profile of cognitive impairment seen in Alzheimer's disease
15. The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia
16. A double-blind, placebo-controlled trial of intravenous flumazenil in Alzheimer's disease
17. Dementia with Lewy Bodies, Alzheimer's Disease and Vascular Dementia show distinct patterns of cognitive impairment
18. Efficacy of rivastigmine in dementia with Lewy bodies: Results of a randomised placebo-controlled international study
19. A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias
20. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale
21. Quantification and characterisation of fluctuating cognition in dementia with Lewy Bodies and Alzheimer's disease
22. Credal classification for dementia screening
23. Use of the Cognitive Drug Research computerised assessment system to measure the efficacy of THA and galanthamine in Alzheimer's disease
24. Pharmacodynamic and early clinical studies with velnacrine
25. The effects of galanthamine on attention in Alzheimer's disease
26. Pharmacodynamic effects of a repeated oral administration of 4 dose levels of S 12024-2 in 36 elderly volunteers
27. Acceptability and clinical activity of 4 weeks treatment by S 12024-2 in 53 in-patients with moderate to severe Alzheimer's disease
28. Cholinesterase inhibitors: Expanding applications